BLUE SKY BREAKOUT

[~ Blue ~]

AEZS~ 3 types of cancer treatment, 2 products in commercialization, 1 adult growth hormone deficiency diagnostic product

1. Via a targeted Molecule, ZopTec. Phase 3 for endometrial cancer and in phase 2 for ovarian and prostate cancer. Partnered with Sinopharm for China
2. An oral vaccin partnered with a German company which will pay for the enterie development, pays an upfront fee, milestones and royalties once commercialized
3. ERK-inhibitors, partnered for 12 months (pre-)clinical testing with a German company, with an option for development and commercialization after 12months testing. Upfront fee, milestones and royalties.
4. Estrogel and Saizen revenues
5. Diagnostic product, called Macrilen, for the diagnosis of Adult Growth Hormone Deficiency, in phase 3 with the potential to become first-in-its'-class

The company has no debt and 50 million dollar in cash, is very conservative.

http://www.aezsinc.com/en/page.php?p=23